Promise and Peril of Natalizumab for MS
These findings demonstrated that natalizumab is effective in patients with relapsing MS; risk for PML was about 1 in 1000 during 18 months of treatment.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)